Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Research Report 2023

Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Research Report 2023


Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.

Highlights

The global Liposomal and Lipid Nanoparticle Drug Delivery Systems market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Liposomal and Lipid Nanoparticle Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal and Lipid Nanoparticle Drug Delivery Systems.
The Liposomal and Lipid Nanoparticle Drug Delivery Systems market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposomal and Lipid Nanoparticle Drug Delivery Systems companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences

Product Type Insights

Global markets are presented by Liposomal and Lipid Nanoparticle Drug Delivery Systems type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Liposomal and Lipid Nanoparticle Drug Delivery Systems are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Liposomal and Lipid Nanoparticle Drug Delivery Systems segment by Type

Liposomes Drugs
Lipid Nanoparticle Drugs

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Liposomal and Lipid Nanoparticle Drug Delivery Systems market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Liposomal and Lipid Nanoparticle Drug Delivery Systems market.
Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Application

Hospital
Retail Pharmacy
Other

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Liposomal and Lipid Nanoparticle Drug Delivery Systems market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid Nanoparticle Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Liposomal and Lipid Nanoparticle Drug Delivery Systems industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid Nanoparticle Drug Delivery Systems.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Liposomal and Lipid Nanoparticle Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Hospital
2.3.3 Retail Pharmacy
2.3.4 Other
2.4 Assumptions and Limitations
3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Breakdown Data by Type
3.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Type (2018-2023)
3.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2023-2028)
4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Breakdown Data by Application
4.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Application (2018-2023)
4.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Perspective (2018-2029)
5.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Growth Trends by Region
5.2.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Historic Market Size by Region (2018-2023)
5.2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2024-2029)
5.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Dynamics
5.3.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Trends
5.3.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Drivers
5.3.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Challenges
5.3.4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Players by Revenue
6.1.1 Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Players by Revenue (2018-2023)
6.1.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2018-2023)
6.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Liposomal and Lipid Nanoparticle Drug Delivery Systems Head office and Area Served
6.4 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Product Type & Application
6.5 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Date of Enter into This Industry
6.6 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)
7.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
7.4 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)
8.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
8.4 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)
9.2 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
9.4 Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)
10.2 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
10.4 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (2018-2029)
11.2 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023)
11.4 Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Detail
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Detail
11.3.2 CSPC Business Overview
11.3.3 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.3.4 CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Detail
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.4.4 Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.5.4 Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Detail
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.7.4 Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Detail
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.8.4 TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Detail
11.9.2 Pacira Business Overview
11.9.3 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.9.4 Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Detail
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.10.4 Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Detail
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.12.4 Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Detail
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Detail
11.14.2 Jazz Business Overview
11.14.3 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.14.4 Jazz Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Detail
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.15.4 Alnylam Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Detail
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.16.4 Bausch Health Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Detail
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.18.4 Takeda Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Detail
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.19.4 Chiesi Farmaceutici Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Detail
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Introduction
11.20.4 Gilead Sciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022)
11.20.5 Gilead Sciences Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2018-2023)
Table 7. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2024-2029)
Table 9. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2018-2023)
Table 11. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2024-2029)
Table 13. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region (2018-2023)
Table 16. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region (2024-2029)
Table 18. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Trends
Table 19. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Drivers
Table 20. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Challenges
Table 21. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Restraints
Table 22. Global Top Liposomal and Lipid Nanoparticle Drug Delivery Systems Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Liposomal and Lipid Nanoparticle Drug Delivery Systems, Headquarters and Area Served
Table 26. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Country (2024-2029) & (US$ Million)
Table 45. Johnson & Johnson Company Detail
Table 46. Johnson & Johnson Business Overview
Table 47. Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 48. Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 49. Johnson & Johnson Recent Development
Table 50. Sun Pharmaceutical Company Detail
Table 51. Sun Pharmaceutical Business Overview
Table 52. Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 53. Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 54. Sun Pharmaceutical Recent Development
Table 55. CSPC Company Detail
Table 56. CSPC Business Overview
Table 57. CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 58. CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 59. CSPC Recent Development
Table 60. Kinyond Company Detail
Table 61. Kinyond Business Overview
Table 62. Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 63. Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 64. Kinyond Recent Development
Table 65. Teva Company Detail
Table 66. Teva Business Overview
Table 67. Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 68. Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 69. Teva Recent Development
Table 70. Fudan-Zhangjiang Company Detail
Table 71. Fudan-Zhangjiang Business Overview
Table 72. Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 73. Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 74. Fudan-Zhangjiang Recent Development
Table 75. Zydus Cadila Company Detail
Table 76. Zydus Cadila Business Overview
Table 77. Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 78. Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 79. Zydus Cadila Recent Development
Table 80. TTY Biopharma Company Detail
Table 81. TTY Biopharma Business Overview
Table 82. TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 83. TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 84. TTY Biopharma Recent Development
Table 85. Pacira Company Detail
Table 86. Pacira Business Overview
Table 87. Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 88. Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 89. Pacira Recent Development
Table 90. Luye Pharma Company Detail
Table 91. Luye Pharma Business Overview
Table 92. Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product
Table 93. Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 94. Luye Pharma Recent Development
Table 95. Leadiant Biosciences Company Detail
Table 96. Leadiant Biosciences Business Overview
Table 97. Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 98. Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 99. Leadiant Biosciences Recent Development
Table 100. Ipsen Company Detail
Table 101. Ipsen Business Overview
Table 102. Ipsen Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 103. Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 104. Ipsen Recent Development
Table 105. Sayre Therapeutics Company Detail
Table 106. Sayre Therapeutics Business Overview
Table 107. Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 108. Sayre Therapeutics Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 109. Sayre Therapeutics Recent Development
Table 110. Jazz Company Detail
Table 111. Jazz Business Overview
Table 112. Jazz Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 113. Jazz Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 114. Jazz Recent Development
Table 115. Alnylam Company Detail
Table 116. Alnylam Business Overview
Table 117. Alnylam Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 118. Alnylam Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 119. Alnylam Recent Development
Table 120. Bausch Health Company Detail
Table 121. Bausch Health Business Overview
Table 122. Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 123. Bausch Health Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 124. Bausch Health Recent Development
Table 125. Acrotech Biopharma Company Detail
Table 126. Acrotech Biopharma Business Overview
Table 127. Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 128. Acrotech Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 129. Acrotech Biopharma Recent Development
Table 130. Takeda Company Detail
Table 131. Takeda Business Overview
Table 132. Takeda Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 133. Takeda Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 134. Takeda Recent Development
Table 135. Chiesi Farmaceutici Company Detail
Table 136. Chiesi Farmaceutici Business Overview
Table 137. Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 138. Chiesi Farmaceutici Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 139. Chiesi Farmaceutici Recent Development
Table 140. Gilead Sciences Company Detail
Table 141. Gilead Sciences Business Overview
Table 142. Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery SystemsProduct
Table 143. Gilead Sciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2017-2022) & (US$ Million)
Table 144. Gilead Sciences Recent Development
Table 145. Johnson & Johnson Company Information
Table 146. Johnson & Johnson Business Overview
Table 147. Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 148. Johnson & Johnson Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 149. Johnson & Johnson Recent Development
Table 150. Sun Pharmaceutical Company Information
Table 151. Sun Pharmaceutical Business Overview
Table 152. Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 153. Sun Pharmaceutical Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 154. Sun Pharmaceutical Recent Development
Table 155. CSPC Company Information
Table 156. CSPC Business Overview
Table 157. CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 158. CSPC Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 159. CSPC Recent Development
Table 160. Kinyond Company Information
Table 161. Kinyond Business Overview
Table 162. Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 163. Kinyond Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 164. Kinyond Recent Development
Table 165. Teva Company Information
Table 166. Teva Business Overview
Table 167. Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 168. Teva Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 169. Teva Recent Development
Table 170. Fudan-Zhangjiang Company Information
Table 171. Fudan-Zhangjiang Business Overview
Table 172. Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 173. Fudan-Zhangjiang Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 174. Fudan-Zhangjiang Recent Development
Table 175. Zydus Cadila Company Information
Table 176. Zydus Cadila Business Overview
Table 177. Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 178. Zydus Cadila Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 179. Zydus Cadila Recent Development
Table 180. TTY Biopharma Company Information
Table 181. TTY Biopharma Business Overview
Table 182. TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 183. TTY Biopharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 184. TTY Biopharma Recent Development
Table 185. Pacira Company Information
Table 186. Pacira Business Overview
Table 187. Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 188. Pacira Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 189. Pacira Recent Development
Table 190. Luye Pharma Company Information
Table 191. Luye Pharma Business Overview
Table 192. Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 193. Luye Pharma Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 194. Luye Pharma Recent Development
Table 195. Leadiant Biosciences Company Information
Table 196. Leadiant Biosciences Business Overview
Table 197. Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery SystemsRevenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 198. Leadiant Biosciences Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 199. Leadiant Biosciences Recent Development
Table 200. Ipsen Company Information
Table 201. Ipsen Business Overview
Table 202. Ipsen Liposomal and Lipid Nanoparticle Drug Delivery SystemsRevenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million)
Table 203. Ipsen Revenue in Liposomal and Lipid Nanoparticle Drug Delivery Systems Business (2018-2023) & (US$ Million) Portfolio
Table 204. Ipsen Recent Development
Table 205. Sayre Therapeutics Company Information
Table 206. Sayre Therapeutics Business Overview
Table

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings